Savara Inc (SVRA) stock is experiencing a significant pre-market surge of 6.32% following a series of positive analyst actions. The biotechnology company has received multiple upgrades and price target increases, boosting investor confidence ahead of the market open.
H.C. Wainwright has made a notable upgrade, raising their rating on Savara from Neutral to Buy. Analyst Andrew Fein has also significantly increased the price target from $2 to $5, citing improved resubmission prospects for the company. Simultaneously, Oppenheimer has raised its price target on Savara from $5 to $6, while maintaining an Outperform rating.
These bullish moves from analysts reflect growing optimism about Savara's potential. According to FactSet, the company now has an average rating of Buy and a mean price target of $7.93. The pre-market rally suggests that investors are responding positively to these upward revisions, potentially anticipating stronger performance from Savara in the near future.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。